JP2018522028A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522028A5
JP2018522028A5 JP2018504750A JP2018504750A JP2018522028A5 JP 2018522028 A5 JP2018522028 A5 JP 2018522028A5 JP 2018504750 A JP2018504750 A JP 2018504750A JP 2018504750 A JP2018504750 A JP 2018504750A JP 2018522028 A5 JP2018522028 A5 JP 2018522028A5
Authority
JP
Japan
Prior art keywords
ibrutinib
btk inhibitor
subject
treatment
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018504750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522028A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/044916 external-priority patent/WO2017023815A1/en
Publication of JP2018522028A publication Critical patent/JP2018522028A/ja
Publication of JP2018522028A5 publication Critical patent/JP2018522028A5/ja
Pending legal-status Critical Current

Links

JP2018504750A 2015-07-31 2016-07-29 ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用 Pending JP2018522028A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562199852P 2015-07-31 2015-07-31
US62/199,852 2015-07-31
US201562221499P 2015-09-21 2015-09-21
US62/221,499 2015-09-21
US201562243432P 2015-10-19 2015-10-19
US62/243,432 2015-10-19
PCT/US2016/044916 WO2017023815A1 (en) 2015-07-31 2016-07-29 Bruton's tyrosine kinase inhibitor combinations and uses thereof

Publications (2)

Publication Number Publication Date
JP2018522028A JP2018522028A (ja) 2018-08-09
JP2018522028A5 true JP2018522028A5 (enExample) 2019-09-19

Family

ID=57885762

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504750A Pending JP2018522028A (ja) 2015-07-31 2016-07-29 ブルトン型チロシンキナーゼ阻害剤の組み合わせ及びそれらの使用

Country Status (10)

Country Link
US (2) US20170027941A1 (enExample)
EP (1) EP3328380A4 (enExample)
JP (1) JP2018522028A (enExample)
CN (1) CN108024996A (enExample)
AU (1) AU2016303659A1 (enExample)
BR (1) BR112018002139A2 (enExample)
CA (1) CA2994161A1 (enExample)
MA (1) MA42546A (enExample)
MX (1) MX2018001369A (enExample)
WO (1) WO2017023815A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
JP2019206516A (ja) * 2018-05-23 2019-12-05 国立大学法人高知大学 膵癌細胞の浸潤転移抑制剤
CN120305263A (zh) * 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
CN111419853B (zh) * 2020-05-27 2022-07-19 德立唯(北京)生物科技有限公司 一种治疗乳腺癌的葫芦素与依鲁替尼组合物
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
US20240285622A1 (en) * 2021-07-30 2024-08-29 Shanghai Aurora Biotechnology Co., Ltd. Pazopanib oral pharmaceutical composition, and preparation method therefor and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009532503A (ja) * 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
JP2013527232A (ja) * 2010-06-02 2013-06-27 アブラクシス バイオサイエンス, エルエルシー 膀胱がんの処置方法
NZ772688A (en) * 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
AU2014251028A1 (en) * 2013-04-08 2015-11-05 Janssen Pharmaceutica Nv Ibrutinib combination therapy
EP2832358A1 (en) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmaceutical kit for use in the treatment of colon and colorectal cancer
EP3033079B1 (en) * 2013-08-12 2018-10-31 Pharmacyclics LLC Methods for the treatment of her2 amplified cancer
CN105899232A (zh) * 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance

Similar Documents

Publication Publication Date Title
JP2025020147A5 (enExample)
JP2013155188A5 (enExample)
JP2016530280A5 (enExample)
JP2020509024A5 (enExample)
AR105027A1 (es) Métodos de tratamiento del cáncer de mama localmente avanzado o metastásico usando antagonistas del eje de pd-1 y taxanos
JP2012193216A5 (enExample)
JP2015536964A5 (enExample)
JP2011079858A5 (enExample)
WO2009099634A3 (en) Picoplatin and amrubicin to treat lung cancer
JP2013522212A5 (enExample)
RU2017134443A (ru) Способ лечения с применением традипитанта
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
JP2015507020A5 (enExample)
JP2013518124A5 (enExample)
FI3511004T3 (fi) Yhdistelmävalmisteita syövän hoitoon
JP2019532047A5 (enExample)
JP2017537927A5 (enExample)
JP2017512194A5 (enExample)
JP2008514577A5 (enExample)
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
JP2023102786A5 (enExample)
JP2017514854A5 (enExample)
JP2024016209A5 (enExample)
JP2017503846A5 (enExample)
JP2021505669A5 (enExample)